Study on Tenofovir Gel for HIV Prevention in Women
Author Information
Author(s): Keller Marla J., Madan Rebecca P., Torres N. Merna, Fazzari Melissa J., Cho Sylvia, Kalyoussef Sabah, Shust Gail, Mesquita Pedro M. M., Louissaint Nicolette, Chen Jianmeng, Cohen Hillel W., Diament Erin C., Lee Anna C., Soto-Torres Lydia, Hendrix Craig W., Herold Betsy C.
Primary Institution: Albert Einstein College of Medicine
Hypothesis
Does the application of 1% Tenofovir gel increase anti-HIV activity in female genital tract secretions?
Conclusion
Tenofovir gel increased anti-HIV activity in cervicovaginal lavage without harming mucosal immunity.
Supporting Evidence
- Women using Tenofovir gel showed significantly higher anti-HIV activity compared to those using placebo.
- The anti-HIV activity persisted even when the virus was introduced in semen.
- Tenofovir gel did not trigger an inflammatory response.
- CVL concentrations of Tenofovir correlated significantly with anti-HIV activity.
Takeaway
The study tested a gel that helps prevent HIV in women, and it worked well without causing harm.
Methodology
30 women applied either 1% Tenofovir or placebo gel daily for 14 days, and anti-HIV activity was measured in cervicovaginal lavage.
Potential Biases
Potential bias in self-reported adherence to gel application.
Limitations
The study was short and conducted among sexually abstinent women, which may not reflect real-world use.
Participant Demographics
Healthy women aged 18-50 from the New York metropolitan area.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website